Cardiorenal Syndrome: Characteristics and Prognostic Impact in Advanced Heart Failure (CARAVEL)
Advanced heart failure (AHF) represents the end stage of chronic heart failure with reduced ejection fraction and affects up to 10% of patients with heart failure. These patients have refractory disease despite optimal guideline-directed medical therapy, and their management is discussed within a multidisciplinary "Heart Team".
Renal dysfunction is highly prevalent in this population. The coexistence of cardiac and renal dysfunction has been classified under the entity of cardiorenal syndrome. Impaired renal function is an independent predictor of adverse cardiovascular and renal outcomes, including death, heart failure decompensation, worsening renal function, and the need for renal replacement therapy. However, patients with AHF remain a particularly complex population, and the lack of longitudinal biological data and limited understanding of the dynamics of cardiorenal syndrome in relation to therapeutic interventions make prognosis assessment and individualized management challenging.
In addition, little is known about renal tubular function in AHF, despite its central role in hydro-electrolytic balance regulation. Biomarkers of tubular injury such as neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) have shown prognostic value in therapeutic studies, but their relationship with cardiac function and outcomes in advanced heart failure remains insufficiently characterized.
The primary objective of this study is to evaluate renal function parameters and their evolution over time through measurement of glomerular filtration rate (GFR) and assessment of tubular function in patients with advanced heart failure, and to investigate their association with major adverse cardiovascular events.
This is a prospective, single-center RIPH2 cohort study including 100 patients aged 18 to 75 years managed for advanced heart failure at the Louis Pradel Cardiovascular Hospital (Hospices Civils de Lyon, France). Patients will be followed according to standard care at 6, 12, 18, and 24 months. More comprehensive nephrological and cardiological evaluations will be performed at baseline, 12 months, and 24 months. Biobanking and quality-of-life questionnaires will also be conducted during these visits. Blood and urine samples will be collected at baseline and 12 months for NGAL et KIM-1 analysis. In addition, a subgroup of 50 consenting patients without contraindications will undergo multiparametric non-contrast renal MRI combined with tissue sodium quantification using 23Na MRI of the leg.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Nathan MEWTON, Pr
- Número de telefone: +33 04 72 35 71 70
- E-mail: nathan.mewton@chu-lyon.fr
Locais de estudo
-
-
Rhone
-
Bron, Rhone, França, 69500
- Hospices Civils de Lyon
-
Contato:
- Nathan MEWTON, Pr
- Número de telefone: +33 04 72 35 71 70
- E-mail: nathan.mewton@chu-lyon.fr
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Written informed consent signed by the patient,
- Age ≥ 18 years and ≤ 75 years,
Patient with advanced heart failure confirmed by criteria of severe cardiac dysfunction documented in a stable condition, with at least one of the following parameters at baseline:
- LVEF ≤ 35%,
- Elevated BNP or NT-proBNP levels (>200 ng/L for BNP and >1000 ng/L for NT-proBNP),
- NYHA class ≥ 3,
- At least one hospitalization for heart failure decompensation within the past 24 months,
- Optimized medical treatment for heart failure according to French/European cardiology guidelines at the maximum tolerated dose for >30 days.
Exclusion Criteria:
- Presence of severe extracardiac disease with a life expectancy < 1 year,
- Patient with end-stage renal disease (GFR <15 mL/min/1.73 m²) or on dialysis,
- History of heart, kidney, or other solid organ transplantation,
- Patient in cardiogenic shock,
- INTERMACS profile ≤ 3,
- Pregnant, parturient, or breastfeeding women*,
- Individuals deprived of liberty by judicial or administrative decision,
- Individuals under psychiatric care,
- Individuals admitted to a health or social institution for purposes other than research,
- Adults under legal protection (guardianship or curatorship),
- Individuals not affiliated with a social security system or equivalent coverage.
- Contraindication to multiparametric renal MRI combined with tissue sodium measurement using non-contrast 23Na MRI of the leg (including inability to undergo MRI as judged by the investigator).
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Patients with cardiorenal syndrome
Patients with cardiorenal syndrome will be followed for 2 years in nephrology and cardiology according to standard of care.
|
Patients with cardiorenal syndrome will be followed for 2 years in nephrology and cardiology according to standard of care.
In addition, as part of the research, they will complete quality-of-life questionnaires and provide blood, urine, and stool samples for testing and biobanking.
An MRI will also be performed for patients participating in the ancillary study.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Occurrence of major cardiovascular events during the first 24 months
Prazo: At 12 and 24 months
|
The primary endpoint of this study is the occurrence of major cardiovascular events during the first 24 months: all-cause mortality, heart transplantation, implantation of a ventricular assist device, hospitalization for heart failure, or worsening ambulatory heart failure. The association between baseline renal function parameters (GFR, NGA, and KIM-1) and the occurrence of events during the first 24 months will be evaluated, as well as the association between renal function parameters at 12 months and the occurrence of major cardiovascular events between 12 and 24 months. |
At 12 and 24 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Blood and urinary levels of NGAL and KIM-1
Prazo: at baseline and at 12 months
|
Blood and urinary measurement of NGAL (neutrophil gelatinase-associated lipocalin) and KIM-1 (kidney injury molecule-1),
|
at baseline and at 12 months
|
|
Occurrence of major adverse renal events
Prazo: at baseline, 12 and 24 months
|
Occurrence of major adverse renal events during the first 24 months: persistent (>30 days) decline in glomerular filtration rate of >40%, initiation of renal replacement therapy, or death due to renal causes. The association between baseline GFR and the occurrence of adverse renal events during the first 24 months will be evaluated, as well as the association between changes in GFR between baseline and 12 months and the occurrence of adverse renal events between 12 and 24 months. Occurrence of major adverse renal events during the first 24 months: persistent (>30 days) decline in glomerular filtration rate of >40%, initiation of renal replacement therapy, or death due to renal causes. The association between baseline GFR and the occurrence of adverse renal events during the first 24 months will be evaluated, as well as the association between changes in GFR between baseline and 12 months and the occurrence of adverse renal events between 12 and 24 months. |
at baseline, 12 and 24 months
|
|
Occurrence of heart failure decompensation events
Prazo: at baseline, 12 and 24 months
|
Occurrence of heart failure decompensation events (hospitalization, ventricular assist device implantation, or outpatient worsening) during the first 24 months.
The association between specific biomarkers of renal tubular injury (serum and urinary NGAL and KIM-1) at baseline and heart failure decompensation events during the first 24 months will be analysed, as well as the association between changes in specific biomarkers of renal tubular injury between baseline and 12 months and the occurrence of heart failure decompensation events between 12 and 24 months.
|
at baseline, 12 and 24 months
|
|
Clinical data collected over a 24-month follow-up period
Prazo: over 24 months
|
Description of the study population over 24 months of follow-up (clinical, paraclinical, therapeutic characteristics, and serious adverse events),
|
over 24 months
|
|
Score of KCCQ questionnaire
Prazo: at baseline, and at 6, 12, 18, and 24 months
|
Each item of KCCQ questionnaire is scored on a 5-point Likert scale and transformed to a 0-100 scale, with higher scores indicating better health status.
|
at baseline, and at 6, 12, 18, and 24 months
|
|
Biomarkers identification
Prazo: At baseline, 12 months and 24 months
|
IBiomarkers identification in biological samples collected in the study biocollection.
|
At baseline, 12 months and 24 months
|
|
Multiparametric renal MRI
Prazo: at baseline and at 12 months
|
Multiparametric renal MRI (BOLD, diffusion, T1 and T2 mapping) in a subgroup of 50 voluntary patients (optional examination)
|
at baseline and at 12 months
|
|
Tissue sodium measurement
Prazo: at baseline and at 12 months.
|
Tissue sodium measurement using 23Na MRI of the leg in a subgroup of 50 voluntary patients (optional examination)
|
at baseline and at 12 months.
|
|
Score of Morisky self-questionnaire MMAS-4
Prazo: at baseline, and at 6, 12, 18, and 24 months,
|
Morisky self-questionnaire MMAS-4 is a generic patient-reported questionnaire used to assess medication adherence.
The scale consists of four items, each scored as 0 for "Yes" and 1 for "No".
The item scores are summed to yield a total score ranging from 0 to 4. Higher scores indicate better medication adherence.
|
at baseline, and at 6, 12, 18, and 24 months,
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 69HCL20_0968
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .